NCT04248335已完成4 期
Physiologic Determinants of PPI Disposition in Children
Children's Mercy Hospital Kansas City2 个研究点 分布在 1 个国家目标入组 76 人开始时间: 2018年7月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 76
- 试验地点
- 2
- 主要终点
- plasma pharmacokinetics of pantoprazole
研究概览
简要总结
This longitudinal study tests the hypothesis that obesity affects drug pharmacology of acid suppression medications in children.
详细描述
The purpose of this research study is to see how the body breaks down certain medicines. Many medicines are broken down in the liver. The liver is an organ in the belly. A person's age, size, genetics (DNA), and the health of their liver decide how quickly the body breaks down medicines and how much medication a person needs to take. Everybody's liver has some fat in it, but the amount of fat is different from person to person. The purpose of this study is to see if the amount of fat in the liver affects how quickly acid suppression medications start and stop working and get removed from the body.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •6-21 years of age
- •Obese and non-obese individuals
- •BMI ≥10th percentile for age (6-20 years of age)
- •BMI ≥18.5 (>20 years of age)
- •Otherwise healthy; or otherwise healthy with diagnosis of GERD, NAFLD, chronic abdominal pain or obesity, according to report of medical history and/or review of the medical record
- •Receiving or not receiving pantoprazole or lansoprazole for routine medical care
- •MRI Hoop Test Clearance
排除标准
- •Unable or unwilling to give written permission/assent/consent
- •For PO Study Drug: Any anatomic abnormality of the GI tract as defined by history, PE, or radiographic findings, including Bariatric surgery, Nissen fundoplication or equivalent surgery.
- •For IV Study Drug: Any anatomic abnormality of the GI tract as defined by history, PE, or radiographic findings, except Bariatric surgery, Nissen fundoplication or equivalent surgery.
- •For subjects undergoing weight management, treatment in the last 7 days with proton pump inhibitors omeprazole, esomeprazole, dexlansoprazole, or grapefruit juice.
- •For subjects not undergoing weight management, treatment in the last 7 days with medications known to clinically significantly inhibit (e.g., omeprazole, esomeprazole, fluoxetine, fluvoxamine, ketoconazole, ticlopidine, felbamate, trazodone, valproic acid, topiramate) or induce (e.g., phenobarbital, carbamazepine, phenytoin) CYP2C19; and those known at therapeutic doses to significantly inhibit (e.g., erythromycin, clarithromycin, grapefruit juice, verapamil, diltiazem, cimetidine, ketoconazole) or induce (e.g., oxcarbazepine, carbamazepine, phenytoin, phenobarbital, St. John's Wort, rifampin, rifapentine) or CYP3A4 activity in the last 7 days.
- •Unable to have blood drawn for the screening lab tests
- •Unable or unwilling to fast overnight prior to the study session
- •Unable to have blood drawn for the screening lab tests
- •If taking lansoprazole or pantoprazole for clinical purposes, unable or unwilling to abstain from that PPI for 3 days prior to PK visit when the PPI is not the same as the study drug for that PK visit
- •Metal in the body or any foreign bodies that precludes MRI sequencing
- •Claustrophobia
- •Exceeds 500lbs or 227 kg in Body Weight
- •Demonstrated adverse reaction to previous pantoprazole or PPI exposure
- •Impaired hepatic activity as determined by routine liver function testing and defined as values ≥ 5 times the age-specific upper limit of normal (ULN) for AST, ALT, total bilirubin >2.0mg/dl, alkaline phosphatase ≥ 5 times the age-specific ULN
- •Impaired renal function defined as creatinine ≥ 3 times the age-specific ULN
- •Females of child-bearing age who are pregnant or breast-feeding
- •Any known infection with hepatitis B, C, or human immunodeficiency virus (HIV)
结局指标
主要结局
plasma pharmacokinetics of pantoprazole
时间窗: 5 years
clearance (CL)
次要结局
- pharmacodynamics(5 years)
- safety of pantoprazole: incidence of reported and gastrointestinal adverse events(5 years)
- pharmacokinetics of midazolam, if medication received to ease discomfort of pH probe study(5 years)
- urinary metabolites(5 years)
研究者
Kate Kyler, MD, MSc
Physician Scientist
Children's Mercy Hospital Kansas City
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
The Effect of PPI Therapy on Weight, Gut Microbiome, and Expression of GPR41 and GPR43Gastroesophageal Reflux DiseaseObesityNCT02457104University of Colorado, Denver120
已完成
2 期
Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)Pancreatic InsufficiencyCystic FibrosisNCT03551691Children's Hospital of Philadelphia19
已完成
1 期
The Impact of Proton Pump Inhibitors on the Fecal MicrobiomeHealthyClostridium Difficile InfectionNCT01822977Mayo Clinic15
撤回
4 期
Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass SurgeryAnastomotic StrictureMorbid ObesityNCT00361985Weill Medical College of Cornell University
招募中
不适用
Obesity effect on the characteristics of the blood-thinning drug rivaroxabavenous thromboembolismobesityatrial fibrillationACTRN12622000297729Medical Research Center, Hamad Medical Corporation81